相关实验视频
Updated: Jun 14, 2025

06:35
Sodium Taurocholate Induced Severe Acute Pancreatitis in C57BL/6 Mice
Published on: June 28, 2021
4.0K
葡萄糖皮质类药物的使用与胰腺炎风险之间的因果关系:孟德尔的随机化研究
Wenfeng Lin1, Qiqi Zheng2, Xiaorong Wang3
1Department of Gastroenterology and Hepatology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
Frontiers in immunology
|September 2, 2024
概括
葡萄糖皮质激素的使用似乎不会因果性地增加胰腺炎的风险. 这项门德尔随机化研究发现,葡萄糖皮质激素使用与不同人群中的急性或慢性胰腺炎之间没有显著的关联.
科学领域:
- 药物基因组学 药物基因组学
- 胃肠病学 胃肠病学
- 流行病学 流行病学
背景情况:
- 葡萄糖皮质激素药物使用与胰腺炎风险之间的关系受到争论.
- 之前的研究已经产生了相互矛盾的结果,需要进一步调查.
研究的目的:
- 调查葡萄糖皮质激素使用与发展胰腺炎的风险之间的潜在因果关系.
- 为了澄清这两个健康状况之间的有争议的联系.
主要方法:
- 使用全基因组关联研究 (GWAS) 数据进行了两样本的门德尔随机化 (MR) 分析.
- 来自欧洲祖先,东亚后裔和FinnGen生物银行联盟的数据被利用.
- 与葡萄糖皮质类药物使用相关的遗传变异被确定为全基因组显著性.
主要成果:
- 在欧洲祖先数据中,没有观察到葡萄糖皮质激素使用与急性胰腺炎 (AP) 或慢性胰腺炎 (CP) 之间的显著因果关系.
- 灵敏度分析 (MR-Egger,MR-PRESSO) 证实了研究结果的稳定性,没有显示出 pleiotropy 或异质性的证据.
- 在FinnGen和东亚数据集中复制的分析产生了一致的结果,支持了主要发现.
结论:
- 这项门德尔随机化研究提供了强有力的证据,证明葡萄糖皮质醇使用与胰腺炎风险之间的因果关系.
- 研究结果表明,葡萄糖皮质激素治疗不会直接导致胰腺炎的发展.
更多相关视频
相关概念视频
Chronic Pancreatitis I: Introduction
84
The pancreas, an elongated and flat gland situated behind the stomach, serves a vital function in digesting food and managing blood sugar levels.
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...
84
Chronic Pancreatitis II: Collaborative Care
77
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
77
Acute Pancreatitis II: Clinical Manifestations and Management
111
Acute pancreatitis presents a complex medical emergency characterized by rapid onset inflammation of the pancreas, demanding timely diagnosis and management to prevent complications. The condition primarily manifests through severe upper abdominal pain that often radiates to the back. This pain intensifies following the consumption of fatty foods. Accompanying symptoms such as nausea, vomiting, abdominal distention, fever, dyspnea, cyanosis, and jaundice can vary in intensity but significantly...
111
Acute Pancreatitis I: Introduction
349
Pancreatitis is inflammation of the pancreas, an organ located behind the stomach. It can be either acute or chronic.
Acute pancreatitis is characterized by rapid inflammation of the pancreas, often caused by factors like gallstone blockage or excessive alcohol consumption. Chronic pancreatitis, on the other hand, is a slow, progressive inflammation that may result from long-term alcohol abuse, obstructions in the pancreatic duct, or genetic factors.
The causes of acute pancreatitis include:
Acute pancreatitis is characterized by rapid inflammation of the pancreas, often caused by factors like gallstone blockage or excessive alcohol consumption. Chronic pancreatitis, on the other hand, is a slow, progressive inflammation that may result from long-term alcohol abuse, obstructions in the pancreatic duct, or genetic factors.
The causes of acute pancreatitis include:
349
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
98
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
98
Glucagon-like Receptor Agonists
306
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
306

